Accession Number:

AD1064689

Title:

Cannabidivarin (CBDV) Versus Placebo in Children with Autism Spectrum Disorder (ASD)

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

Albert Eintsein College of Medicine, Inc.

Personal Author(s):

• Hollander, Eric

Report Date:

2018-08-01

Pagination or Media Count:

42

Abstract:

The CDC currently estimates 1 in 59 children have Autism Spectrum Disorder ASD. Children with ASD have problems with social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and a high caregiver burden. The only medications approved by the FDA for symptoms of ASD are aripiprazole and risperidone. Both of these are used to reduce irritability but have short-term and long-term side effects.

Descriptors:

• health services
• medical personnel
• autism
• drug abuse
• intellectual disability
• epilepsy
• anticonvulsants
• brain
• institutional review board
• therapy
• biomedical research
• brain injuries
• new york
• pharmacies
• seizures
• united states
• materials
• neurodevelopmental disorders
• psychiatry
• blood

Subject Categories:

• Medicine and Medical Research
• Psychology

Distribution Statement:

[A, Approved For Public Release]